Suppr超能文献

健康供体与未经治疗的慢性淋巴细胞白血病患者的初始嵌合抗原受体T细胞扩增潜力的差异

Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients.

作者信息

Hoffmann Jean-Marc, Schubert Maria-Luisa, Wang Lei, Hückelhoven Angela, Sellner Leopold, Stock Sophia, Schmitt Anita, Kleist Christian, Gern Ulrike, Loskog Angelica, Wuchter Patrick, Hofmann Susanne, Ho Anthony D, Müller-Tidow Carsten, Dreger Peter, Schmitt Michael

机构信息

Cellular Immunotherapy, GMP Core Facility, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.

National Center for Tumor Diseases (NCT), Heidelberg, Germany.

出版信息

Front Immunol. 2018 Jan 10;8:1956. doi: 10.3389/fimmu.2017.01956. eCollection 2017.

Abstract

INTRODUCTION

Therapy with chimeric antigen receptor T (CART) cells for hematological malignancies has shown promising results. Effectiveness of CART cells may depend on the ratio of naive (T) vs. effector (T) T cells, T cells being responsible for an enduring antitumor activity through maturation. Therefore, we investigated factors influencing the T/T ratio of CART cells.

MATERIALS AND METHODS

CART cells were generated upon transduction of peripheral blood mononuclear cells with a CD19.CAR-CD28-CD137zeta third generation retroviral vector under two different stimulating culture conditions: anti-CD3/anti-CD28 antibodies adding either interleukin (IL)-7/IL-15 or IL-2. CART cells were maintained in culture for 20 days. We evaluated 24 healthy donors (HDs) and 11 patients with chronic lymphocytic leukemia (CLL) for the composition of cell subsets and produced CART cells. Phenotype and functionality were tested using flow cytometry and chromium release assays.

RESULTS

IL-7/IL-15 preferentially induced differentiation into T, stem cell memory (T: naive CD27+ CD95+), CD4+ and CXCR3+ CART cells, while IL-2 increased effector memory (T), CD56+ and CD4+ T regulatory (T) CART cells. The net amplification of different CART subpopulations derived from HDs and untreated CLL patients was compared. Particularly the expansion of CD4+ CART cells differed significantly between the two groups. For HDs, this subtype expanded >60-fold, whereas CD4+ CART cells of untreated CLL patients expanded less than 10-fold. Expression of exhaustion marker programmed cell death 1 on CART cells on day 10 of culture was significantly higher in patient samples compared to HD samples. As the percentage of malignant B cells was expectedly higher within patient samples, an excessive amount of B cells during culture could account for the reduced expansion potential of CART cells in untreated CLL patients. Final T/T ratio stayed <0.3 despite stimulation condition for patients, whereas this ratio was >2 in samples from HDs stimulated with IL-7/IL-15, thus demonstrating efficient CART expansion.

CONCLUSION

Untreated CLL patients might constitute a challenge for long-lasting CART effects since only a low number of T among the CART product could be generated. Depletion of malignant B cells before starting CART production might be considered to increase the T/T ratio within the CART product.

摘要

引言

嵌合抗原受体T(CART)细胞治疗血液系统恶性肿瘤已显示出有前景的结果。CART细胞的有效性可能取决于初始T细胞与效应T细胞的比例,T细胞通过成熟负责持久的抗肿瘤活性。因此,我们研究了影响CART细胞T/T比例的因素。

材料与方法

在两种不同的刺激培养条件下,用CD19.CAR-CD28-CD137ζ第三代逆转录病毒载体转导外周血单个核细胞来产生CART细胞:添加白细胞介素(IL)-7/IL-15或IL-2的抗CD3/抗CD28抗体。CART细胞在培养中维持20天。我们评估了24名健康供者(HD)和11名慢性淋巴细胞白血病(CLL)患者的细胞亚群组成并制备了CART细胞。使用流式细胞术和铬释放试验检测表型和功能。

结果

IL-7/IL-15优先诱导分化为初始T、干细胞记忆T(初始CD27+CD95+)、CD4+和CXCR3+CART细胞,而IL-2增加效应记忆T、CD56+和CD4+调节性T(Treg)CART细胞。比较了来自HD和未经治疗的CLL患者的不同CART亚群的净扩增情况。特别是两组之间CD4+CART细胞的扩增有显著差异。对于HD,该亚型扩增>60倍,而未经治疗的CLL患者的CD4+CART细胞扩增少于10倍。与HD样本相比,培养第10天时患者样本中CART细胞上耗竭标志物程序性细胞死亡1的表达显著更高。由于患者样本中恶性B细胞的百分比预期更高,培养期间过量的B细胞可能是未经治疗的CLL患者中CART细胞扩增潜力降低的原因。尽管对患者采用了刺激条件,但最终的T/T比例仍<0.3,而在用IL-7/IL-15刺激的HD样本中该比例>2,从而证明了CART的有效扩增。

结论

未经治疗的CLL患者可能对CART的持久效果构成挑战,因为在CART产物中只能产生少量的初始T细胞。在开始制备CART之前清除恶性B细胞可能会提高CART产物中的T/T比例。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验